Dronca, Roxana

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

Robert, C., Ribas, A., Wolchok, J. D., Hodi, F. S., Hamid, O., Kefford, R., Weber, J. S., Joshua, A. M., Hwu, W.-J., Gangadhar, T. C., et al. (2014) · The Lancet

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 1,774

Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma

Ribas, A., Hamid, O., Daud, A., Hodi, F. S., Wolchok, J. D., Kefford, R., Joshua, A. M., Patnaik, A., Hwu, W.-J., Weber, J. S., et al. (2016) · JAMA

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 1,069

Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma

Daud, A. I., Wolchok, J. D., Robert, C., Hwu, W.-J., Weber, J. S., Ribas, A., Hodi, F. S., Joshua, A. M., Kefford, R., Hersey, P., et al. (2016) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 665

Immune checkpoint inhibitor toxicities

Marin-Acevedo, J. A., Chirila, R. M., & Dronca, R. S. (2019) · Mayo Clinic Proceedings

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 160